Cochrane · systematic review · CD007687
Mifepristone for uterine fibroids
Tristan, M, Orozco, LJ, Steed, A, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 14 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Mifepristone for uterine fibroids
Population: patients with uterine fibroids
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relief of bleedingPictorial bleeding charts | OR 17.84 [6.72, 47.38] | 2 studies · 77 participants | Low Downgraded: risk of bias |
Reduction in average fibroid volumeScale from: 0 to 100 | no estimate extracted | 3 studies · 99 participants | Low Downgraded: risk of bias |
Reduction in uterine volumeScale from: 0 to 100 | no estimate extracted | 2 studies · 72 participants | Low Downgraded: risk of bias |
Adverse events | OR 31.65 [4.83, 207.35] | 2 studies · 54 participants | Low Downgraded: risk of bias |
Mifepristone (10 mg/day/3 months) compared to placebo for uterine fibroids
Population: patients with uterine fibroids
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leiomyoma volume (mL) Mifepristone (10 mg/day/3 months) vs placebo | no estimate extracted | 1 study · 35 participants | Low Downgraded: risk of bias |
Uterine volume(mL) Mifepristone (10 mg/day/3 months) vs placebo | no estimate extracted | 1 study · 35 participants | Low Downgraded: risk of bias |
Relief of bleedingdichotomic Mifepristone (10 mg/day/3 months) vs placebo | OR 27.02 [7.25, 100.7] | 1 study · 35 participants | Low Downgraded: risk of bias |
Relief of pelvic paindichotomic Mifepristone (10 mg/day/3 months) vs placebo | OR 2.1 [0.38, 11.71] | 1 study · 26 participants | Low Downgraded: risk of bias |
Relief of dysmenorrhoeadichotomic Mifepristone (10 mg/day/3 months) vs placebo | OR 10.93 [2.37, 50.51] | 1 study · 26 participants | Low Downgraded: risk of bias |
Mifepristone (50 mg/1 day after/3 months) compared to placebo for uterine fibroids
Population: patients with uterine fibroids
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leiomyoma volume(mL). Scale from: 0 to 100. Mifepristone (50 mg/1 day after/3 months) vs placebo | no estimate extracted | 1 study · 30 participants | Low |
Cystic glandular dilatationdichotomic Mifepristone (50 mg/1 day after/3 months) vs placebo | OR 16.67 [1.36, 204.03] | 1 study · 19 participants | Low |
Mifepristone (5 mg/day/6 months) versus placebo for uterine fibroids
Population: patients with uterine fibroids
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relief of bleedingdichotomic Mifepristone (5 mg/day/6 months) vs placebo | OR 2.22 [0.54, 9.13] | 1 study · 42 participants | Low |
Leiomyoma volume(mL) Mifepristone (5 mg/day/6 months) vs placebo | no estimate extracted | 1 study · 37 participants | Low |
Uterine volume(mL) Mifepristone (5 mg/day/6 months) vs placebo | no estimate extracted | 1 study · 37 participants | Low |